Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Effect of the Head Computed Tomography Choice Decision Aid in Parents of Children With Minor Head Trauma
Homme, James L. , Kharbanda, Anupam B. , Tzimenatos, Leah, Louie, Jeffrey P. , Cohen, Daniel M. , Westphal, Jessica J., Shah, Nilay D. , Inselman, Jonathan , Ferrara, Michael J. , Kuppermann, Nathan , Hess, Erik P. , Nigrovic, Lise E. , Herrin, Jeph , Montori, Víctor M.

Mayo Clinic

JAMA Network Open | October 17, 2018 | Volume: 1 | Issue: 5 | Pages: e182430

10.1001/jamanetworkopen.2018.2430 | PMID 30646167 Get It

The stem cell market and policy options: a call for clarity
Zarzeczny, Amy , Illes, Judy , Master, Zubin , Robillard, Julie M. , Turner, Leigh , Zettler, Patricia J. , Master, Zubin , Atkins, Harold L. , Kimmelman, Jonathan , Snyder, Jeremy , Caulfield, Timothy

Mayo Clinic

Journal of Law and the Biosciences | October 15, 2018 | Volume: 5 | Issue: 3 | Pages: 743-758

10.1093/jlb/lsy025 | PMID 31143461 Get It

Prediction of Arteriovenous Fistula Clinical Maturation from Postoperative Ultrasound Measurements: Findings from the Hemodialysis Fistula Maturation Study
Robbin, Michelle L. , Greene, Tom , Allon, Michael , Dember, Laura M. , Imrey, Peter B. , Cheung, Alfred K. , Kaufman, James S. , Radeva, Milena , Shiu, Yan-Ting , Vazquez, Miguel A. , Umphrey, Heidi , Alexander, Lauren F. , Abts, C., Beck, Gerald J. , Kusek, John W., Feldman, Harold I. , Group, the Hemodialysis Fistula Maturation Study, Alexander, Lauren, Alexander, Lauren F , Greene, Tom , Himmelfarb, Jonathan , Huber, Thomas S. , Roy‐Chaudhury, Prabir , Group, the Hemodialysis Fistula Maturation Study

Mayo Clinic

Journal of the American Society of Nephrology | October 11, 2018 | Volume: 29 | Issue: 11 | Pages: 2735-2744

10.1681/asn.2017111225 | PMID 30309898 Get It

Background The utility of early postoperative ultrasound measurements in predicting arteriovenous fistula (AVF) clinical maturation is uncertain. Methods We investigated the relationships of ultrasound parameters with AVF clinical maturation in newly created AVF, measured at 1 day and 2 and 6 weeks, in 602 participants of a multicenter, observational cohort study. A backward elimination algorithm identified ultrasound measurements that independently predicted unassisted and overall AVF maturation. Candidate variables included AVF blood flow, diameter, and depth, upper arm arterial diameter, presence of stenosis, presence of accessory veins, seven case-mix factors (age, sex, black race, AVF location, diabetes, dialysis status, and body mass index), and clinical center. We evaluated the accuracy of the resulting models for clinical prediction. Results At each ultrasound measurement time, AVF blood flow, diameter, and depth each predicted in a statistically significant manner both unassisted and overall clinical maturation. Moreover, neither the remaining ultrasound parameters nor case-mix factors were associated with clinical AVF maturation after accounting for blood flow, diameter, and depth, although maturation probabilities differed among clinical centers before and after accounting for these parameters. The crossvalidated area under the receiver operating characteristic curve for models constructed using these three ultrasound parameters was 0.69, 0.74, and 0.79 at 1 day and 2 and 6 weeks, respectively, for unassisted AVF clinical maturation and 0.69, 0.71, and 0.76, respectively, for overall AVF maturation. Conclusions AVF blood flow, diameter, and depth moderately predicted unassisted and overall AVF clinical maturation. The other factors considered did not further improve AVF maturation prediction.
Never Events in Radiology and Strategies to Reduce Preventable Serious Adverse Events
Ponce, Lisa , Osborn, Howard H., Jokerst, Clinton, Ponce, Lisa M, Flug, Jonathan A.

Mayo Clinic

RadioGraphics | October 10, 2018 | Volume: 38 | Issue: 6 | Pages: 1823-1832

10.1148/rg.2018180036 | PMID 30303781 Get It

The Road to Wellness: Engagement Strategies to Help Radiologists Achieve Joy at Work
Fishman, Michael , Siewert, Bettina , Bender, Claire E., Kruskal, Jonathan B. , Fishman, Michael D C, Mehta, Tejas S, Siewert, Bettina , Kruskal, Jonathan B , Mehta, Tejas S.

Mayo Clinic

RadioGraphics | October 10, 2018 | Volume: 38 | Issue: 6 | Pages: 1651-1664

10.1148/rg.2018180030 | PMID 30303794 Get It

Establishing a Core Outcome Measure for Life Participation: A Standardized Outcomes in Nephrology-kidney Transplantation Consensus Workshop Report
Ju, Angela , Jowsey‐Gregoire, Sheila G. , Tan, Jane C. , Taylor, Quinetta, Dobbels, Fabienne , Caskey, Fergus , Jha, Vivekanand , Locke, Jayme E. , Hanson, Camilla S., Sautenet, Bénédicte , Manera, Karine , Craig, Jonathan C. , Howell, Martin , Rutherford, Claudia , Tong, Allison , Watson, Christopher J.E. , Malone, Andrew F. , Jowsey-Gregoire, Sheila, Howell, Martin , Josephson, Michelle A. , Butt, Zeeshan A. , Fowler, Kevin John , Knoll, Greg A. , Ahn, Curie

Mayo Clinic

Transplantation | October 9, 2018 | Volume: 103 | Issue: 6 | Pages: 1199-1205

10.1097/tp.0000000000002476 | PMID 30300284 Get It

Background. Kidney transplantation confers substantial survival and quality of life benefits for many patients with end-stage kidney disease compared with dialysis, but complications and side effects of immunosuppression can impair participation in daily life activities. Life participation is a critically important patient-reported outcome for kidney transplant recipients but is infrequently and inconsistently measured in trials. We convened a consensus workshop on establishing an outcome measure for life participation for use in all trials in kidney transplantation. Methods. Twenty-five (43%) kidney transplant recipients/caregivers and 33 (57%) health professionals from 8 countries participated in 6 facilitated breakout group discussions. Transcripts were analyzed thematically. Results. Four themes were identified. Returning to normality conveyed the patients’ goals to fulfill their roles (ie, in their family, work, and community) and reestablish a normal lifestyle after transplant. Recognizing the diverse meaning and activities of “life” explicitly acknowledged life participation as a subjective concept that could refer to different activities (eg, employment, recreation, family duties) for each individual patient. Capturing vulnerability and fluctuations posttransplant (eg, due to complications and side-effects) distinguished between experiences in the first year posttransplant and the long-term impact of transplantation. Having a scientifically rigorous, feasible, and meaningful measure was expected to enable consistent and frequent assessment of life participation in trials in kidney transplantation. Conclusions. A feasible and validated core outcome measure for life participation is needed so that this critically important patient-reported outcome can be consistently and meaningfully assessed in trials in kidney transplantation to inform decision making and care of recipients.
Ultrasound-Guided Cubital Tunnel Decompression in a Collegiate Swimmer: A Case Report
Boettcher, Brennan J. , Finnoff, Jonathan T.

Mayo Clinic

Clinical Journal of Sport Medicine | October 9, 2018 | Volume: 30 | Issue: 1 | Pages: e15-e17

10.1097/jsm.0000000000000680 | PMID 30300144 Get It

Abstract: A 19-year-old female collegiate swimmer presented to our sports medicine clinic with a history and physical examination consistent with right ulnar neuropathy at the cubital tunnel. Diagnostic ultrasound (US) revealed compression of the ulnar nerve under the cubital tunnel retinaculum (CTR) with nerve swelling proximal to the site of compression. Electrodiagnostic studies confirmed the diagnosis of a moderate to severe ulnar neuropathy at the elbow. Treatment consisted of an US-guided decompression of the ulnar nerve in the cubital tunnel by cutting the CTR using a rotated stylet “v” cutting technique. The patient's symptoms resolved, and she was able to begin a swimming progression 2 weeks after the procedure. After completion of this progression, she was able to successfully resume full, unrestricted competitive collegiate swimming without return of her symptoms. To the best of our knowledge, this is the first description of an US-guided cubital tunnel decompression surgery.
Abstract WP346: Frequency of Convexal Subarachnoid Hemorrhage in the General Population
Yost, Micah D. , Fiebelkorn, Catherine Arnold, Aakre, Jeremiah A. , Przybelski, Scott A. , Klaas, James P. , Petersen, Ronald, Graff‐Radford, Jonathan , Vemuri, Prashanthi , Rabinstein, Alejandro A. , Flemming, Kelly D. , Brown, Robert , Kantarci, Kejal , Mielke, Michelle M. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Stroke | October 8, 2018 | Volume: 49 | Issue: Suppl_1 | Pages: No page available

10.1161/str.49.suppl_1.wp346 Get It

Background: Non-traumatic convexal subarachnoid hemorrhages (cSAH) in the elderly can be a manifestation of cerebral amyloid angiopathy (CAA) and predict future intracerebral hemorrhage risk. The frequency of cSAH in the elderly population is unknown. Our objective was to determine the frequency of convexal subarachnoid hemorrhage in a population-based study among individuals who underwent amyloid PET imaging. Methods: Between 11/29/2004 and 3/11/2017 there were 1,687 participants ages 50-years and older in the population-based Mayo Clinic Study of Aging (MCSA) with Pittsburgh compound B (PiB) PET imaging. All intracerebral hemorrhages among participants were identified utilizing the Rochester Epidemiology Project’s records linkage system, and records and images were reviewed to identify those with both symptomatic and asymptomatic convexal subarachnoid hemorrhage. Neuroimaging characteristics, demographics, medications, and ApoE genotype were recorded. Results: Four (0.23%) cSAHs were identified among the individuals who underwent PiB PET imaging. Three were women and median age was 73 (range: 67-84). cSAH occurred in the following locations: right frontal (3), and right parieto-occipital (1). Two went on to develop a lobar intracerebral hemorrhage at a median of 4.75 years after cSAH. Coexisting cerebral microbleeds were identified in one case. The APOE allele combinations of the four participants were: 3/3, 3/3, 2/2, and 2/3. On PiB PET imaging, the median SUVR was 1.81 (range: 1.38-2.34). Conclusion: cSAH is a relatively rare manifestation of CAA occurring in less than 1% of the general population, but may represent a subset with a high risk of future intracerebral hemorrhage. Half of the participants with cSAH had an APOE e2 allele.
Abstract WMP56: Genetics of Acute Ischemic Lesion Volume: the MRI-Genetics Interface Exploration (MRI-GENIE) Study
Xu, Huichun , Donahue, Kathleen, McArdle, Patrick F. , Jiménez-Conde, Jordi , Kleindorfer, Dawn , Schmidt, Reinhold, Sharma, Pankaj , Słowik, Agnieszka , Woo, Daniel , Worrall, Bradford B. , Kittner, Steven J. , Rosand, Jonathan, Golland, Polina , Rost, Natalia S. , Giese, Anne‐Katrin , Schirmer, Markus D. , Dalca, Adrian Vasile , Gaynor, Brady J. , Cole, John W. , Broderick, Joseph P. , Jern, Christina , Kissela, Brett , Lemmens, Robin , Lindgren, Arne G. , Rundek, Tatjana , Sacco, Ralph L. , Thijs, Vincent , Meschia, James F. , Rosand, Jonathan M. , Mitchell, Braxton D. , Wu, Ona

Mayo Clinic

Stroke | October 8, 2018 | Volume: 49 | Issue: Suppl_1 | Pages: No page available

10.1161/str.49.suppl_1.wmp56 Get It

Introduction: Genome-wide association (GWA) studies have contributed substantially to the understanding of complex vascular traits including ischemic stroke; however, genetic determinants of acute cerebral ischemia remain to be elucidated. Objective: To investigate the genetic architecture of cerebral infarct lesion burden in patients with acute ischemic stroke (AIS). Methods: Twelve international sites contributed 3,301 AIS subjects with acute MRI and genome-wide genotyping to the MRI-GENIE study. In a preliminary analysis of 657 subjects of European ancestry, acute cerebral infarct lesions were outlined on diffusion-weighted images (DWI) using a semi-automated volumetric method. Standard quality control measures were performed per single nucleotide polymorphism (SNP) and per subject. SNPs were imputed to the Haplotype Reference Consortium v1.1 panel. Natural log-transformed DWI volume was used for GWA analysis with allelic dosage per SNP, age, sex and principal components 1-5 of genetic ancestry as covariates. Results: GWA testing for DWI volume in 7.7 million SNPs yielded no signal crossing the Bonferroni-corrected genome-wide significance threshold of p <5*10 -8 . However, several loci passed the nominal significance threshold of p <1*10 -6 (Figure 1), including a locus on chromosome 2 in the SPATA3-AS1 (spermatogenesis associated 3 antisense RNA 1) gene (lead SNP: rs2368999, MAF=36%, p =8.4*10 -7 ) and an intronic locus on chromosome 10 in the ATRNL1 (Attractin like 1) gene (lead SNP: rs592284, MAF=10%, p =9.1*10 -7 ). Conclusion: In this first-to-date, preliminary GWAS of acute cerebral infarct volume in AIS patients, we identified several new, nominally significant loci including a locus in ATRNL1, a gene previously linked to carotid plaque burden. Further analyses of the MRI-GENIE cohort to replicate these findings, to include stroke subtype specific analyses, and to increase the overall statistical power of the study are ongoing.
Abstract 189: Identifying Patients at Highest Risk of Developing Atrial Fibrillation and the Role of Remote Prior Stroke: Insights From the REVEAL AF Study
Elkind, Mitchell S, Kowey, Peter R. , Halperin, Jonathan L. , Ziegler, Paul , Pouliot, Erika , Reiffel, James A. , Wachter, Rolf , Verma, Atul , Gersh, Bernard J.

Mayo Clinic

Stroke | October 8, 2018 | Volume: 49 | Issue: Suppl_1 | Pages: No page available

10.1161/str.49.suppl_1.189 Get It

Introduction: Recent trials using insertable cardiac monitors (ICMs) show high rates of atrial fibrillation (AF) in those at risk of developing AF based on demographics. Further identifying subsets who could benefit most from ICMs is desirable. We evaluated if the recently-developed HAVOC risk score which has predicted AF in cryptogenic stroke patients also predicts AF detection by ICMs in those without a recent stroke. Methods: Participants from the prospective REVEAL AF study, which reported frequent clinically unrecognized AF in patients at risk for AF (CHADS 2 scores ≥3 or =2 with ≥1 additional risk factor), with ICM data and not on anti-arrhythmic drugs were included. Ischemic stroke <1 year ago excluded participation. HAVOC scores were calculated using points for hypertension (2), age ≥75 (2), valvular disease (2), vascular disease (1), obesity (1), congestive heart failure (4), and coronary artery disease (2). Prior stroke, an AF outcome, generally not a cause, is not included. Score classification is: low (0-4), intermediate (5-9), or high (10-14). Corresponding AF detection rates were compared via the log-rank test. Results: Among 391 participants, 95 (24%), 241 (62%), and 55 (14%) had low, intermediate, and high HAVOC scores, respectively. At 18 months, AF incidence was significantly less for those with low (19.5%) vs intermediate (32.1%) or high (34.2%) scores (p=0.045, Figure). At 18 months, AF incidence was similar among those with (n=79) vs. without (n=312) a history of remote stroke (27.1% vs. 29.9%; p>0.05, median time from stroke to ICM insertion=4 years). Conclusions: The HAVOC risk score identified a subset of high risk individuals at greatest risk of developing AF. AF incidence rates were similar among those with and without prior remote stroke. Remote strokes may not be a strong predictor of AF in this population. HAVOC scores could be a useful approach to identify those at high likelihood of manifesting AF, as best documented by long-term monitoring.